Whole Exome Sequencing

WES is the analysis of the protein-coding regions of all ~20,000 genes of the human genome (known as the exome) using next-generation sequencing technologies. While the exome constitutes only ~1% of the whole genome, ~85% of all established disease-causing variants are located within the exome.

The diagnostic yield of WES is higher than many traditional genetic diagnostic methods such as multi-gene panels. A diagnosis is made in 20% to 60% of cases with severe, early onset disorders having the highest diagnostic rates.

WES is most suitable for individuals with:

  • A complex, nonspecific genetic disorder with multiple differential diagnoses
  • A genetically heterogeneous disorder where stepwise testing of genes significantly increases costs
  • A suspected genetic disorder where a specific genetic test is not available
  • Previous genetic testing that has not been diagnostic

Last modified: 20 November 2017

All WES orders from North and South America include copy number variant diagnostics (Plus analysis). Our flagship WES offering is the Whole Exome Family Plus test, which includes WES for the index patient and biological parents. Other family members can be analyzed upon request. Details include:

  • WES and deletion/duplication (copy number variant) analysis for the proband and the biological parents
  • Including parental samples provides the following benefits:
    • Improved variant filtering and analysis
    • Reduced rate of uncertain findings
    • Increased diagnostic rate
    • Reduced overall turnaround time

In addition, we also offer the following:

  • Whole Exome Plus – Proband only WES and deletion/duplication (copy number variants) analysis

Last modified: 20 February 2018


Test Test code Considerations
Whole Exome Plus WE0301
  • When biological parents are NOT available
Whole Exome Family Plus WE0401
  • Both biological parents are available
  • The most comprehensive reporting and interpretation of variants is desired at the time the report is issued

Last modified: 20 February 2018

High-quality exome capture is performed using an in-house–designed WES platform and the Illumina NovaSeq sequencing system.

Last modified: 20 November 2017

We have performed an extensive assay validation to determine the coverage, accuracy and precision of our WES data.

Highly uniform sequencing depth across all protein-coding genes:

  • On average, median sequencing depth of 174X
  • On average, ≥99.4% of the base pairs (bp) in target coding regions covered at ≥20X

Highly sensitive and specific detection of SNVs and indels

  • 99.7% sensitivity and >99.99 specificity for SNV detection within target coding regions
  • 97% sensitivity and >99.99% specificity for indel detection within target coding regions (up to 220 bp)

Excellent sensitivity for the detection of copy number variants (CNVs)

  • Most 1 exon deletions detected and >99% sensitivity to detect 5 exon del/dup
  • 100% sensitivity to detect known microdeletion and microduplication syndromes

Deep intronic disease-causing variants included in every WES

  • Assessment of >1500 noncoding disease-causing variants listed in ClinVar and HGMD are included in every WES

Assay performs with high precision

  • The within run precision (repeatability) is 99.7% for SNVs

Last modified: 20 November 2017

Yes. The median sequencing depth and ≥20x coverage are reported for each individual included in the WES analysis. In addition, we include a coverage plot detailing the target region coverage for each individual included in the WES analysis.

Last modified: 20 November 2017

We do not report coverage for individual genes on the WES report. If there is a gene or a differential diagnosis that you suspect, please include this information with the referral. Our interpretation team will specifically examine your gene(s) of interest at the time of reporting.

Last modified: 20 November 2017

Yes, Blueprint Genetics includes assessment of deletions or duplications (CNVs) for all of our Whole Exome products. The detection limit for Del/Dup (CNV) analysis varies throughout the genome depending on exon size, sequencing coverage, and sequence content. In our validation study, 92% of single exon deletions were detected.

Last modified: 20 February 2018

Our WES products detect variants in nuclear encoded mitochondrial genes. At this time, mtDNA variants are not targeted in our WES.

Last modified: 20 November 2017

WES generates thousands of variants. Our proprietary bioinformatics pipeline distinguishes disease-relevant variants from the many benign variants present in the exome. The pipeline determines the consequence of variants and performs filtering steps to remove common variants based on allele frequencies in population cohorts. We review the literature and various databases to determine the association between the identified variants and the genes’ association with relevant diseases.

To further aid the process of variant interpretation, observed variants are matched against a comprehensive set of databases of disease-related mutations which are collected and curated in-house, and/or accessed from the public domain or licensed from commercial sources.

The analysis of the WES data is individually tailored. During the analysis process, the clinical and family history of the patient, including symptoms, age of onset, prevalence, and inheritance patterns are taken into consideration. The precise filters used in the variant analysis are then selected based on this information.

Last modified: 20 November 2017

Blueprint Genetics analyzes WES data using a ‘genotype-first’ approach. In the genotype-first approach, the genetic data are primarily utilized to establish the diagnosis. This is in contrast to the ‘phenotype-first’ approach where WES data are filtered for genes that are known to be associated with the symptoms observed in the patient. The genotype-first approach allows for a diagnosis of an unexpected or atypical presentation of a disorder associated with previously established disease genes.

The WES data are first analyzed for variants in genes that are known to be associated with conditions showing overlap with that of the patient. If this is inconclusive, the data are then analyzed for variants that are not located within known clinically associated genes, but have properties that make them candidates for potentially disease–causing variants.

Variants are reported based on the clinical information provided. It is therefore extremely important to provide detailed clinical information with the patient sample to maximize the diagnostic yield of the genotype-first approach.

If, over time, other patients with similar phenotypes and variants in the same gene are identified, the variant may be reclassified as a likely cause of the disorder. In this circumstance, an updated report will be sent to the ordering clinician.

Last modified: 20 November 2017

As WES covers all protein-coding genes of the genome, it enables detection of variants that are not associated with the indication for performing WES but are of medical value for patient care. These findings are known as secondary findings.

Blueprint Genetics follows the ACMG Recommendations for Reporting Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update to seek and report clinically actionable variants in genes determined by ACMG. These guidelines are followed if the patient or caregiver has opted-in for analysis and reporting of secondary findings.

To receive the reporting of secondary findings, the ordering healthcare provider will need to provide us with a consent form signed by the patient before we begin the analysis. This can be attached to the order in Nucleus or sent to our laboratory via fax or landmail. More information and the consent form is available here. 

If parents or other family members are also participating in the WES analysis, they have the option to opt-in for analysis and reporting of secondary findings.

Secondary findings for additional family members are reported in a separate clinical statement than that of the index patient and is independent of the secondary findings reported in the index patient.

Last modified: 20 November 2017

Family members participating in WES for the benefit of segregation analysis and variant interpretation in the proband may have a variant(s) in a gene(s) unrelated to the proband’s phenotype that is not reported.

If an individual (or their caregiver) participating in WES does not opt in to analysis and reporting of secondary findings, a disease-causing variant may be present and not reported.

Further, variants that are benign or likely benign are considered negative and therefore these variants are not generally reported.

Last modified: 20 November 2017

To view a sample WES report, please click here.

Last modified: 20 November 2017

Results are available within 8-10 weeks from receipt of (all required) samples, consent forms, and billing requirements.

Last modified: 20 November 2017

While we do not offer a formal expedited WES service at this time, we will do our best to accommodate requests for expedited WES results if there is a clinical indication to do so. Please contact our Support team for additional information.

Last modified: 20 November 2017

Family members can be tested for variants identified by WES as part of our Familial Variant Testing (FVT) service. For more information, please click here.

Last modified: 20 November 2017

If samples are received on the index patient and one or more family members, all variants and segregation analysis relating to the cause of the index patient’s phenotype are reported in the index patient’s report.  

Secondary findings for family members participating in WES are reported in separate, individual reports if the family member chooses to receive this information. Otherwise, there will not be separate family member reports. 

Last modified: 20 November 2017

At this time, we do not accept prenatal samples for WES from ongoing pregancies; however, we are able to accept fetal samples for WES from a deceased fetus.

Please note, only extracted fetal DNA is accepted at this time. In addition, Blueprint Genetics currently does not offer maternal cell contamination (MCC) studies. Therefore, ordering clinicians need to ensure that any prenatal sample sent to Blueprint Genetics has MCC studies done locally.

Blueprint Genetics will accept prenatal samples for panel testing or Family Member Testing (FMT) at our standard fee when requested.

Last modified: 20 November 2017

An extensive WES Re-analysis service is available. For additional information, please read more here or contact our Support team.

Last modified: 20 November 2017

Yes, we provide raw data for WES orders. Read more about raw data here.

Last modified: 20 November 2017

  • At present, it is not possible to capture and sequence 100% of the exome. We cover, on average, >99.4% of base pairs with at least 20X depth within the target coding regions.
  • WES is not optimized to detect certain variants such as trinucleotide repeats and may not reliably detect variants in genes with pseudogenes or segmental duplication.
  • At this time, we are not targeting variants in mtDNA.
  • This test is not designed to detect complex inversions, gene conversions, or balanced translocations.
  • This test is not designed to detect variants in regulatory or noncoding (intronic variants located deeper than 20 nucleotides from the exon-intron boundary) regions, however, we are specifically targeting >1500 noncoding disease-causing variants listed in ClinVar and HGMD.
  • This test may not reliably detect low-level mosaicism or stretches of mononucleotide repeats.
  • A negative result does not exclude a genetic condition.
  • It is possible that a variant is identified in a gene not currently known to be associated with disease. Given the incomplete knowledge of the function of all the genes in the genome, this variant may not be recognized as a factor in a patient’s disease.

Last modified: 20 November 2017

Please click here for information regarding pricing.

Last modified: 20 November 2017

  • Sample from the index patient (see below for sample types accepted).
  • Completed requisition for the index patient.
  • Completed consent form for the index patient. To receive the reporting of secondary findings, please ensure the correct box is selected for opting in, and the form is sent to Blueprint Genetics before we begin analysis.
  • Detailed clinical information including consult notes, symptoms, and age(s) of onset pedigree, previous test results (genetic and others like ECG, MRI, etc). It is strongly preferred that these are provided in English.
  • Samples from additional family members, if applicable.
  • Consent forms for additional family members, if applicable.

If Whole Exome Family Plus is being ordered, please send parental/familial and index patient samples at the same time.

Last modified: 20 November 2017

  • Blood (min. 1 mL) in an EDTA tube
  • Extracted DNA, min. 2 μg in TE buffer or equivalent
  • Saliva (Please see the accepted saliva kits on our Sample Requirements page)

Read more about our sample requirements here.

Last modified: 20 November 2017